EDIT - Editas Medicine - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

EDIT is currently covered by 15 analysts with an average price target of $3.06. This is a potential upside of $1.83 (148.78%) from yesterday's end of day stock price of $1.23.

Editas Medicine's activity chart (see below) currently has 91 price targets and 103 ratings on display. The stock rating distribution of EDIT is 54.55% BUY, 40.91% HOLD and 4.55% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 44.24% with an average time for these price targets to be met of 135.56 days.

Highest price target for EDIT is $12, Lowest price target is $1, average price target is $3.06.

Most recent stock forecast was given by GENA WANG from BARCLAYS on 13-Dec-2024. First documented stock forecast 29-Feb-2016.

Currently out of the existing stock ratings of EDIT, 24 are a BUY (54.55%), 18 are a HOLD (40.91%), 2 are a SELL (4.55%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$3

$1.69 (129.01%)

$5

12 days ago
(13-Dec-2024)

5/10 (50%)

$1.51 (101.34%)

235

Buy

$3

$1.69 (129.01%)

$11

12 days ago
(13-Dec-2024)

3/7 (42.86%)

$1.51 (101.34%)

28

Buy

$19

12 days ago
(13-Dec-2024)

1/9 (11.11%)

$9.69 (104.08%)

617

Buy

$8

$6.69 (510.69%)

$18

12 days ago
(13-Dec-2024)

1/5 (20%)

$6.51 (436.91%)

26

Hold

$4

$2.69 (205.34%)

$5

12 days ago
(13-Dec-2024)

3/9 (33.33%)

$2.51 (168.46%)

59

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is EDIT (Editas Medicine) average time for price targets to be met?

On average it took 135.56 days on average for the stock forecasts to be realized with a an average price target met ratio 44.24

Which analyst has the current highest performing score on EDIT (Editas Medicine) with a proven track record?

STEVEN SEEDHOUSE

Which analyst has the most public recommendations on EDIT (Editas Medicine)?

Steven Seedhouse works at RAYMOND JAMES and has 22 price targets and 19 ratings on EDIT

Which analyst is the currently most bullish on EDIT (Editas Medicine)?

Cory Kasimov with highest potential upside - $21.82

Which analyst is the currently most reserved on EDIT (Editas Medicine)?

Greg Harrison with lowest potential downside - -$0.31

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?